DUBLIN--(BUSINESS WIRE)--The "Artificial Intelligence in Drug Discovery Market Research Report by Offering (Services and Software), Application, End User, Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2026 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering.
The Global Artificial Intelligence in Drug Discovery Market size was estimated at USD 566.22 million in 2020, USD 701.05 million in 2021, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 25.06% to reach USD 2,166.65 million by 2026.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Artificial Intelligence in Drug Discovery Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Artificial Intelligence in Drug Discovery Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Artificial Intelligence in Drug Discovery Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Artificial Intelligence in Drug Discovery Market?
4. What is the competitive strategic window for opportunities in the Global Artificial Intelligence in Drug Discovery Market?
5. What are the technology trends and regulatory frameworks in the Global Artificial Intelligence in Drug Discovery Market?
6. What is the market share of the leading vendors in the Global Artificial Intelligence in Drug Discovery Market?
7. What modes and strategic moves are considered suitable for entering the Global Artificial Intelligence in Drug Discovery Market?
Market Dynamics
Drivers
- Demand to Control Drug Discovery Process and Reduce Cost
- Increasing Need to Manage the Large Data Generated During Preclinical Studies
- Increasing Adoption across Biopharmaceutical Companies
Restraints
- Unavailability of Skilled Professionals
Opportunities
- AI Cloud to Create a Streamlined and Automated Approach in Drug Discovery
- Increasingly Growing R&D Investments
Challenges
- Limited Availability of Data Sets
Companies Mentioned
- Aria Pharmaceuticals
- Atomwise, Inc.
- BenevolentAI Limited
- BioSymetrics Inc.
- Cloud Pharmaceuticals, Inc.
- Cyclica Inc.
- Deep Genomics Incorporated
- Envisagenics, Inc.
- Exscientia
- Insitro, Inc.
- International Business Machines Corporation
- Microsoft Corporation
- Novartis AG
- NVIDIA Corporation
- Owkin, Inc.
- Verge Genomics Inc.
- XtalPi Inc.
For more information about this report visit https://www.researchandmarkets.com/r/mgxxoa
